Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

被引：0

作者：

Guarino, Michael J.

Starodub, Alexander

Masters, Gregory A.

Heist, Rebecca Suk

Messersmith, Wells A.

Bardia, Aditya

Ocean, Allyson J.

Thomas, Sajeve Samuel

Maliakal, Pius P.

Wegener, William A.

Sharkey, Robert M.

Wilhelm, Francois

Goldenberg, David M.

机构：

[1] Christiana Care Hlth Syst, Helen F Graham Canc Ctr, Newark, DE USA

[2] Indiana Univ Hlth, Goshen Ctr Canc Care, Goshen, IN USA

[3] Helen F Graham Canc Ctr, Newark, DE USA

[4] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA

[5] Univ Colorado Canc Ctr, Aurora, CO USA

[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Univ Florida, Windermere, FL USA

[9] Immunomedics Inc, Morris Plains, NJ USA

[10] Garden State Canc Ctr, Ctr Mol Med & Immunol, Morris Plains, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.2504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2504

引用

页数：1

共 50 条

[1] Therapy of metastatic, non-small cell lung cancer (mNSCLC) with the anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132).
Camidge, D. Ross
Heist, Rebecca Suk
Masters, Gregory A.
Scheff, Ronald J.
Starodub, Alexander
Messersmith, Wells A.
Bardia, Aditya
Ocean, Allyson J.
Horn, Leora
Berlin, Jordan
Maliakal, Pius P.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
Guarino, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
Bardia, Aditya
Vahdat, Linda T.
Diamond, Jennifer Robinson
Starodub, Alexander
Moroose, Rebecca L.
Isakoff, Steven J.
Ocean, Allyson J.
Berlin, Jordan
Messersmith, Wells A.
Thomas, Sajeve Samuel
Wilhelm, Francois
Wegener, William A.
Maliakal, Pius P.
Sharkey, Robert M.
Goldenberg, David M.
Mayer, Ingrid A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[3] Therapy of Advanced Metastatic Lung Cancers with an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132: Interim Phase II Clinical Results
Camidge, D. R.
Starodub, Aleander N.
Ocean, Allyson
Messersmith, Wells A.
Bardia, Aditya
Thomas, Sajeve S.
Masters, Gregory
Heist, Rebecca
Maliakal, Pius
Govindan, Serengulam
Sharkey, Robert M.
Wilhelm, Francois E.
Goldenberg, David M.
Guarino, Michael J.
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S173 - S173
[4] Treatment for metastatic platinum resistant urothelial cancer (PRUC) with an anti-Trop2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
Tagawa, Scott T.
Faltas, Bishoy
Lam, Elaine
Messersmith, Wells A.
Saylor, Philip
Bardia, Aditya
Hajdenberg, Julio J.
Morgans, Alicia K.
Berlin, Jordan D.
Lim, Emerson
Kalinsky, Kevin
Maliakal, Pius
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
Ocean, Allyson J.
CANCER RESEARCH, 2016, 76
[5] Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.
Bardia, Aditya
Diamond, Jennifer Robinson
Messersmith, Wells A.
Mayer, Ingrid A.
Isakoff, Steven J.
Abramson, Vandana Gupta
Berlin, Jordan
Starodub, Alexander
O'Shaughnessy, Joyce
Kalinsky, Kevin
Moroose, Rebecca L.
Shah, Nikita C.
Juric, Dejan
Shapiro, Geoffrey
Guarino, Michael J.
Ocean, Allyson J.
Wilhelm, Francois
Sharkey, Robert M.
Goldenberg, David M.
Vahdat, Linda T.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18)
[6] Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Ocean, Allyson J.
Starodub, Alexander N.
Bardia, Aditya
Vahdat, Linda T.
Isakoff, Steven J.
Guarino, Michael
Messersmith, Wells A.
Picozzi, Vincent J.
Mayer, Ingrid A.
Wegener, William A.
Maliakal, Pius
Govindan, Serengulam V.
Sharkey, Robert M.
Goldenberg, David M.
CANCER, 2017, 123 (19) : 3843 - 3854
[7] Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience
Starodub, Alexander
Ocean, Allyson J.
Messersmith, Wells A.
Picozzi, Vincent J.
Guarino, Michael J.
Bardia, Aditya
Thomas, Sajeve Samuel
Berlin, Jordan
Shah, Manish A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).
Tagawa, Scott T.
Ocean, Allyson J.
Lam, Elaine Tat
Saylor, Philip James
Bardia, Aditya
Hajdenberg, Julio
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[9] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
Bardia, A.
Diamond, J. R.
Mayer, I. A.
Isakoff, S. J.
Abramson, V.
Starodub, A. N.
O'Shaughnessy, J.
Kalinsky, K.
Moroose, R.
Shah, N.
Juric, D.
Shapiro, G. I.
Guarino, M.
Ocean, A. J.
Messersmith, W. A.
Berlin, J. D.
Wegener, W. A.
Sharkey, R. M.
Goldenberg, D. M.
Vahdat, L. T.
CANCER RESEARCH, 2017, 77
[10] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)
Goldenberg, David M.
Cardillo, Thomas M.
Govindan, Serengulam V.
Rossi, Edmund A.
Sharkey, Robert M.
ONCOTARGET, 2015, 6 (26) : 22496 - 22512

← 1 2 3 4 5 →